

Supplementary Table.

References: (I): Intensive production; (B): Backyard production; (MAR index) Multiple antibiotic resistance index; (VI) Virulence genes index; (LN): Mesenteric lymph nodes.

Isolate	Serotype	Source	Type of production	Location	Year	Antibiotic resistance profiles	MAR index	Virulence genes	VI
88	Agona	Feaces	I	Bs. As.	2012		0	<i>sopB-ssaQ-mgtC-avrA-siiD-bcfC</i>	0,6
87	Agona	LN	I	Bs. As.	2012		0	<i>sopB-ssaQ-mgtC-avrA-bcfC</i>	0,5
82	Agona	Feaces	I	Bs. As.	2013		0	<i>sopB-ssaQ-mgtC-avrA-sodC1-siiD-bcfC</i>	0,7
84	Agona	Gallbladder	I	Bs. As.	2013	AMP-CLR-TET-NAL	0,27	<i>sopB-ssaQ-mgtC-avrA-siiD-bcfC</i>	0,6
113	Agona	Feaces	I	Bs. As.	2012	CLR-TET-NAL	0,20	<i>sopB-ssaQ-mgtC-avrA-siiD</i>	0,5
98	Anatum	Gallbladder	I	Bs. As.	2012		0	<i>sopB-ssaQ-mgtC-avrA-siiD-bcfC</i>	0,6
99	Anatum	Feaces	I	Bs. As.	2014		0	<i>sopB-ssaQ-mgtC-avrA-siiD-bcfC</i>	0,6
111	Anatum	Feaces	I	Bs. As.	2013		0	<i>sopB-ssaQ-mgtC-avrA-siiD-bcfC</i>	0,6
12/18-465	Bredeney	Feaces	B	Bs. As.	2018		0	<i>sopB-ssaQ-mgtC-avrA-siiD</i>	0,5
165/17-H	Cerro	Feaces	I	Bs. As.	2017	AMP-CEP-CLR-TET-NAL-ENR	0,40	<i>sopB-ssaQ-mgtC-avrA-siiD-bcfC</i>	0,6
165/17-P	Cerro	Feaces	I	Bs. As.	2017	AMP-TMS-CLR-TET-NAL-ENR	0,40	<i>sopB-ssaQ-mgtC-avrA-siiD-bcfC</i>	0,6
78	Cholerasuis	Feaces	I	Bs. As.	2012		0	<i>sopB-ssaQ-avrA-siiD-bcfC</i>	0,5
2335/17 MJ	Cholerasuis	LN	I	Cordoba	2017	TMS-TET	0,13	<i>sopB-ssaQ-mgtC-spyC-sodC1-siiD-bcfC</i>	0,7
93	Derby	Gallbladder	I	Bs. As.	2013	AMP-CLR-TET-NAL	0,27	<i>sopB-ssaQ-mgtC-avrA-siiD-bcfC</i>	0,6
89	Derby	Feaces	I	Bs. As.	2013	AMP-TMS-GEN-TET-NAL-CIPR-ENR	0,47	<i>sopB-ssaQ-mgtC-avrA-siiD-bcfC</i>	0,6
85	Derby	Feaces	I	Bs. As.	2013	CLR-NAL	0,13	<i>sopB-ssaQ-mgtC-avrA-sodC1-bcfC</i>	0,6

<b>2344/17 MJ</b>	Derby	Feaces	I	Cordoba	2017		0	<i>sopB-ssaQ-mgtC-avrA-sopE1-siiD-bcfC</i>	0,7
<b>174/17- 3</b>	Derby	Feaces	I	Bs. As.	2017	AMP-CEP-CFO-CLR-TET-NAL-ENR	0,47	<i>sopB-ssaQ-mgtC-avrA-siiD-bcfC</i>	0,6
<b>133/18- C</b>	Derby	Feaces	I	Misiones	2018	AMP-CLR-TET-NAL	0,27	<i>sopB-ssaQ-mgtC-avrA-siiD-bcfC</i>	0,6
<b>12/18- 464</b>	Enteritidis	Feaces	B	Bs. As.	2018		0	<i>sopB-ssaQ-mgtC-avrA-siiD</i>	0,5
<b>12/18- 466</b>	Lille	Feaces	B	Bs. As.	2018		0	<i>sopB-ssaQ-mgtC-siiD</i>	0,4
<b>26/17</b>	Lindenburg	Feaces	B	Bs. As.	2017	AMP-CFO-CLR-TET-NAL-CIPR-ENR	0,47	<i>sopB-ssaQ-mgtC-avrA-sodC1-sopE1-siiD-bcfC</i>	0,8
<b>96</b>	Liverpool	LN	I	Bs. As.	2012		0	<i>sopB-ssaQ-mgtC-avrA-siiD-bcfC</i>	0,6
<b>97</b>	Liverpool	Gallbladder	I	Bs. As.	2012		0	<i>sopB-ssaQ-mgtC-avrA-siiD-bcfC</i>	0,6
<b>100</b>	Liverpool	Gallbladder	I	Bs. As.	2012		0	<i>sopB-ssaQ-mgtC-avrA-siiD-bcfC</i>	0,6
<b>114/17- G16</b>	Mbandaka	Feaces	I	Santa Fe	2017	AMP-TMS-CLR-TET	0,27	<i>sopB-ssaQ-mgtC-avrA-siiD-bcfC</i>	0,6
<b>31/17</b>	Newport	Feaces	I	Bs. As.	2017	CFTIO	0,07	<i>sopB-ssaQ-mgtC-avrA-sodC1-sopE1-siiD-bcfC</i>	0,8
<b>12/18- 463</b>	Newport	Feaces	B	Bs. As.	2018		0	<i>sopB-ssaQ-mgtC-avrA-sopE1-siiD</i>	0,6
<b>174/17- 5</b>	Ohio	Feaces	I	Bs. As.	2017	AMP-CFO-CLR-TET-NAL-ENR	0,40	<i>sopB-ssaQ-mgtC-siiD-bcfC</i>	0,5
<b>174/17- 6</b>	Ohio	Feaces	I	Bs. As.	2017	AMP-CLR-TET-ENR	0,27	<i>sopB-ssaQ-mgtC-siiD-bcfC</i>	0,5
<b>83</b>	Rissen	Feaces	I	Bs. As.	2013	CLR-ENR	0,13	<i>sopB-ssaQ-mgtC-avrA-gipA-sodC1-siiD-bcfC</i>	0,8
<b>86</b>	Rissen	Feaces	I	Bs. As.	2013	CLR-ENR	0,13	<i>sopB-ssaQ-mgtC-avrA-gipA-sodC1-bcfC</i>	0,7
<b>79</b>	Rissen	Feaces	I	Bs. As.	2012	CLR-ENR	0,13	<i>sopB-ssaQ-mgtC-avrA-</i>	0,6

										<i>sodC1-siiD</i>
<b>291/16</b>	Rissen	Feaces	B	Bs. As.	2016	TMS-ENR	0,13	<i>sopB-ssaQ-mgtC-avrA-</i> <i>sodC1-sopE1-siiD-bcfC</i>	0,8	
<b>108</b>	Schwarzengrund	Gallbladder	I	Bs. As.	2012		0	<i>sopB-ssaQ-mgtC-avrA- siiD-</i> <i>bcfC</i>	0,6	
<b>110</b>	Schwarzengrund	Gallbladder	I	Bs. As.	2012	GEN-CLR-TET	0,20	<i>sopB-ssaQ-mgtC-avrA-</i> <i>sodC1-siiD</i>	0,6	
<b>105/17-1</b>	Schwarzengrund	Feaces	B	Bs. As.	2017		0	<i>sopB-ssaQ-mgtC-avrA-bcfC</i>	0,5	
<b>105/17-2</b>	Schwarzengrund	Feaces	B	Bs. As.	2017		0	<i>sopB-ssaQ-mgtC-avrA-bcfC</i>	0,5	
<b>12/18-467</b>	Schwarzengrund	Feaces	B	Bs. As.	2018		0	<i>sopB-ssaQ-mgtC-avrA-</i> <i>sopE1-siiD</i>	0,6	
<b>12/18-468</b>	Stanleyville	Feaces	B	Bs. As.	2018		0	<i>sopB-ssaQ-mgtC-avrA-</i> <i>sopE1-siiD</i>	0,6	
<b>95</b>	Thompson	LN	I	Santa Fe	2013	TET-NAL	0,13	<i>sopB-ssaQ-mgtC-avrA- siiD-</i> <i>bcfC</i>	0,6	
<b>175</b>	Typhimurium	LN	I	Bs. As.	2013	AMP-TMS-GEN-TET-NAL-CIPR-ENR	0,47	<i>sopB-ssaQ-mgtC-avrA-gipA-</i> <i>sodC1-siiD-bcfC</i>	0,8	
<b>183</b>	Typhimurium	Gallbladder	I	Bs. As.	2012	AMP-TMS-GEN-TET-NAL-CIPR-ENR	0,47	<i>sopB-ssaQ-mgtC-avrA-gipA-</i> <i>sodC1-siiD-bcfC</i>	0,8	
<b>90</b>	Typhimurium	LN	I	Bs. As.	2013	AMP-TMS-GEN-TET-NAL-CIPR-ENR	0,47	<i>sopB-ssaQ-mgtC-avrA-gipA-</i> <i>sodC1-siiD-bcfC</i>	0,8	
<b>94</b>	Typhimurium	Gallbladder	I	Bs. As.	2012	AMP-TMS-GEN-TET-NAL-CIPR-ENR	0,47	<i>sopB-ssaQ-mgtC-avrA-</i> <i>sodC1-siiD-bcfC</i>	0,7	
<b>186</b>	Typhimurium	LN	I	Bs. As.	2013	AMP-TMS-GEN-TET-NAL-CIPR-ENR	0,47	<i>sopB-ssaQ-mgtC-avrA-</i> <i>sodC1-siiD-bcfC</i>	0,7	
<b>2351/17 MJ</b>	Typhimurium	Feaces	I	Cordoba	2017	AMP-CEP-TMS-GEN-CLR-TET-NAL-CIPR-ENR	0,60	<i>sopB-ssaQ-mgtC-avrA-gipA-</i> <i>sodC1-sopE1-siiD-bcfC</i>	0,9	
<b>165/17-ABC</b>	Typhimurium	Feaces	I	Bs. As.	2017	AMP-CEP-CLR-TET-NAL-CIPR-ENR	0,47	<i>sopB-ssaQ-mgtC-avrA-gipA-</i> <i>sodC1-siiD-bcfC</i>	0,8	

<b>165/17-EFG</b>	Typhimurium	Feaces	I	Bs. As.	2017	AMP-CEP-GEN-CLR-TET-NAL-CIPR-ENR	0,53	<i>sopB-ssaQ-mgtC-avrA-gipA-sodC1-siiD-bcfC</i>	0,8
<b>197/17-A</b>	Typhimurium	LN	B	Bs. As.	2017	AMP-CEP-GEN-TET-NAL-ENR	0,40	<i>sopB-ssaQ-mgtC-avrA-gipA-sodC1-sopE1-siiD-bcfC</i>	0,9
<b>194/17-E</b>	Typhimurium	Feaces	I	Neuquen	2017	AMP-CEP-GEN-TET-NAL-ENR	0,40	<i>sopB-ssaQ-mgtC-avrA-gipA-sodC1-sopE1-siiD-bcfC</i>	0,9
<b>194/17-G</b>	Typhimurium	Feaces	I	Neuquen	2017	AMP-CEP-GEN-TET	0,27	<i>sopB-ssaQ-mgtC-avrA-spvC-sodC1-siiD-bcfC</i>	0,8
<b>04/18-A</b>	Typhimurium	Feaces	I	Bs. As.	2018	CFTIO-TET	0,13	<i>sopB-ssaQ-mgtC-avrA-spvC-sodC1-siiD</i>	0,7
<b>64</b>	(4,12:i:-)	Gallbladder	I	Bs. As.	2012	AMP-CEP-CFX-CFTIO-FEP-TMS-GEN-TET-NAL-CIPR-ENR-AZT	0,80	<i>sopB-ssaQ-mgtC-avrA-gipA-sodC1-sopE1-siiD-bcfC</i>	0,9
<b>92</b>	(4,12:i:-)	Gallbladder	I	Bs. As.	2012	AMP-TMS-GEN-TET-NAL-CIPR-ENR	0,47	<i>sopB-ssaQ-mgtC-avrA-gipA-sodC1-siiD-bcfC</i>	0,8
<b>63</b>	(4,12:i:-)	Gallbladder	I	Bs. As.	2012	AMP-TMS-GEN-TET-NAL-CIPR-ENR	0,47	<i>sopB-ssaQ-mgtC-avrA-sodC1-siiD-bcfC</i>	0,7
<b>81</b>	Westhampton	LN	I	Bs. As.	2012		0	<i>sopB-ssaQ-mgtC-avrA-siiD-bcfC</i>	0,6
<b>165/17-D</b>	Worthington	Feaces	I	Bs. As.	2017	AMP-CEP-GEN-CLR-TET-NAL-ENR	0,47	<i>sopB-ssaQ-mgtC-avrA-siiD-bcfC</i>	0,6
<b>165/17-MNO</b>	Worthington	Feaces	I	Bs. As.	2017	AMP-CLR-TET-NAL-ENR	0,33	<i>sopB-ssaQ-mgtC-avrA-siiD-bcfC</i>	0,6